Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

atrial fibrillation - antithrombotics - primary prevention of thromboembolic events


Related trials

ENGAGE-AF TIMI 48 High dose, 2013 - edoxaban vs warfarin standard dose

ARISTOTLE, 2011 - apixaban vs warfarin standard dose

AVERROES, 2011 - apixaban vs aspirin

ROCKET-AF, 2010 - rivaroxaban vs warfarin standard dose

ACTIVE A, 2009 - aspirin + clopidogrel vs aspirin

RE-LY (150mg), 2009 - dabigatran 150mg vs warfarin standard dose

RE-LY (110mg), 2009 - dabigatran 110mg vs warfarin standard dose

Lip (phase 2 AZD0837), 2009 - AZD0837 vs warfarin standard dose

AMADEUS, 2008 - idraparinux vs warfarin standard dose

PETRO (150mg), 2007 - dabigatran 150mg vs warfarin standard dose

ACTIVE W, 2006 - aspirin + clopidogrel vs anticoagulant

Japanese AF Trial, 2006 - aspirin vs control

SPORTIF V, 2005 - ximelagatran vs warfarin standard dose

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004 - triflusal+coumadin medium dose vs coumadin standard dose

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004 - triflusal+coumadin medium dose vs triflusal

WASH (aspirin), 2004 - aspirin vs no treatment

NASPEAF (triflusal vs coumadin standard dose)), 2004 - triflusal vs coumadin standard dose

SAFT(warfarin low dose + aspirin vs no treatment), 2003 - warfarin low dose + aspirin vs control

SPORTIF III, 2003 - ximelagatran vs warfarin standard dose

SPORTIF II (ximelagatran vs warfarin standard dose), 2002 - ximelagatran vs warfarin standard dose

PATAF (coumadin low dose vs coumadin standard dose), 1999 - coumadin low dose vs coumadin standard dose

PATAF (vs coumadin standard dose), 1999 - aspirin vs coumadin standard dose

LASAF(aspirin vs no treatment), 1999 - aspirin vs control

PATAF (vs coumadin low dose), 1999 - aspirin vs coumadin low dose

AFASAK II (aspirin vs warfarin low dose), 1998 - aspirin vs warfarin low dose



See also:

  • All atrial fibrillation clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of aspirin
  •  
     PATAF (vs coumadin low dose) study, 1999 TRC2616 
    download pdf: aspirin | antithrombotics for atrial fibrillation

    Treatments

    Studied treatment aspirin 300mg/d
    Control treatment coumarin low dose(target INR 1.1-1.6 )
    Remarks The PATAF trial includes 2 strata: -patients eligible for standard intensity coumarin:randomly assigned to standard anticoagulation(INR 2.5-3.5),very low intensity anticoagulation(INR 1.1-1.6) or aspirin(150mg/d). -patients ineligible for standard anticoagulation:randomly assigned to very low intensity anticoagulation(INR 1.1-1.6) or aspirin(150mg/d).

    Patients

    Patients non rheumatic AF,recruited in general practice,with no established indication for anticoagulation.
    Inclusion criteria age >60;chronic or intermittent AF confirmed by ECG within the 2 past years;no established indication for coumarin
    Exclusion criteria General exclusion criteria:treatable cause of AF;previous stroke;rheumatic valvular disease,myocardial infarction or cardiovascular surgery in past year;cardiomyopathy(left ventricular ejection < 40%;chronic heart failure;cardiac aneurysm;history of systemic embolism;retinal infarction;coumarin use in the past 3 month;contra-indications for aspirin or coumarin;pacemaker;life expectancy < 2 years. Exclusion criteria for standard anticoagulation:age >78;retinopathy;ventricular or duodenal ulcer;history of gastro-intestinal or genito-urinary bleeding;diastolic blood pressure>105 mmHg or systolic pressure >185 mmHg or both.
    Remarks We took all patients who were given aspirin (strate 1+2) and all patients on low dose anticoagulation(strate 1+2).
    Baseline characteristics
    age(mean) 75.2 
    male(%) 44.9 
    systolic blood pressure(mean) 151.25 
    diastolic blood pressure(mean) 84.25 
    hypertension(%) 40.6 
    diabete mellitus(%) 16 
    prior myocardial infarction(%)
    paroxysmal AF(%) 15.3 
    current smoker(%) 9.5 
    subgroup test

    Method and design

    Randomized effectives 319 / 279 (studied vs. control)
    Design Parallel groups
    Blinding Simple aveugle
    Follow-up duration 2.7 years
    Lost to follow-up no lost to follow up
    Geographic area Netherlands
    Hypothesis non inferiority
    Primary endpoint stroke,systemic embolism,major haemorrhage and vascular death
    Remarks The study was carried out to show that aspirin is equivalent to warfarin, but the methodology used was inappropriate.The study team conducted an intention to treat analysis and assumed they could conclude to equivalence if no significant difference was found between treatments at the end of the study.But this hypothesis is wrong :if no difference has been found,no conclusion is possible,and particularly, equivalence can't be proven.
    Withdrawals (T1/T0) 16.9% / 25.8%


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    thrombo-embolic event (cerebral or systemic)

    23 / 319
    16 / 279
    classic 1,26 [0,68;2,33]

    stroke (fatal and non fatal)

    22 / 319
    18 / 279
    1,07 [0,59;1,95]

    ischemic stroke

    17 / 319
    15 / 279
    0,99 [0,50;1,95]

    All cause death

    66 / 319
    41 / 279
    classic 1,41 [0,99;2,01]

    Cardiovascular death

    34 / 319
    28 / 279
    1,06 [0,66;1,71]

    Fatal stroke

    8 / 319
    4 / 279
    classic 1,75 [0,53;5,75]

    TE event or ischemic stroke or systemic embolism

    23 / 319
    16 / 279
    classic 1,26 [0,68;2,33]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    thrombo-embolic event (cerebral or systemic) 23 / 319 (7,2%) 16 / 279 (5,7%) 1,26 [0,68;2,33]  
    stroke (fatal and non fatal) 22 / 319 (6,9%) 18 / 279 (6,5%) 1,07 [0,59;1,95] classified as ischemic or hemorrhagic according to computed tomography 
    ischemic stroke 17 / 319 (5,3%) 15 / 279 (5,4%) 0,99 [0,50;1,95]  
    All cause death 66 / 319 (20,7%) 41 / 279 (14,7%) 1,41 [0,99;2,01]  
    Cardiovascular death 34 / 319 (10,7%) 28 / 279 (10,0%) 1,06 [0,66;1,71] within 4 weeks after stroke,systemic embolism,myocardial infarction,congestive heart failure or major bleeding or sudden death 
    Fatal stroke 8 / 319 (2,5%) 4 / 279 (1,4%) 1,75 [0,53;5,75]  
    TE event or ischemic stroke or systemic embolism 23 / 319 (7,2%) 16 / 279 (5,7%) 1,26 [0,68;2,33] thrombo-embolic event, ischemic stroke or systemic embolism 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction (for a follow-up of 2.7 years)
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    thrombo-embolic event (cerebral or systemic) 7,21% 5,73% 1,5%
    stroke (fatal and non fatal) 6,90% 6,45% 0,44%
    ischemic stroke 5,33% 5,38% -0,05%
    All cause death 20,69% 14,70% 6,0%
    Cardiovascular death 10,66% 10,04% 0,62%
    Fatal stroke 2,51% 1,43% 1,1%
    TE event or ischemic stroke or systemic embolism 7,21% 5,73% 1,5%

    Meta-analysis of all similar trials:

    antithrombotics in atrial fibrillation for primary prevention of thromboembolic events



    Reference(s)

    TrialResults-center ID TRC2616
    Trials register # NA
    • Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, van Ree JW, Knottnerus JA. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.. BMJ 1999 Oct 9;319:958-64
      Pubmed | Hubmed | Fulltext

    (c) 2004-2015 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels